# Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/PRLD/prelude-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-update
Ticker: PRLD
Company: Prelude Therapeutics
Source: Prelude Therapeutics
Published: 2025-11-12 12:01 EST
Original Source URL: https://investors.preludetx.com
## Summary

Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 Preclinical data from JAK2V617F JH2 inhibitor program and

## Article Body
Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 Preclinical data from JAK2V617F JH2 inhibitor program and
## Recent Company News
- 2026-05-12 11:01 EST — [Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Prelude Therapeutics
- 2026-04-20 10:30 EST — [Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-pricing-of-90-0-million-underwritten-offering) — Source: Prelude Therapeutics
- 2026-04-20 10:00 EST — [Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-presents-preclinical-data-from-development-candidate-prt13722-a-first-in-class-orally-bioavailable-potent-and-highly-selective-kat6a-degrader-at-american-association-for-cancer-research-aacr-annual-meeting-2026) — Source: Prelude Therapeutics
- 2026-04-15 11:30 EST — [Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-the-appointment-of-charles-morris-m-d-as-chief-medical-officer) — Source: Prelude Therapeutics
- 2026-03-17 20:31 EST — [Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-acceptance-of-preclinical-abstract-for-prt13722-a-first-in-class-oral-kat6a-selective-degrader-at-the-2026-aacr-annual-meeting) — Source: Prelude Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)